Vident Investment Advisory, LLC Beam Therapeutics Inc. Transaction History

Vident Investment Advisory, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	SELL	$29.32 - $35.99 $19,116 - $23,465	-652 Reduced 5.5%	11,205 $357,000
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $100,610 - $162,812	3,337 Added 39.17%	11,857 $363,000
Q4 2022 Feb 14, 2023	BUY	$36.73 - $51.6 $12,598 - $17,698	343 Added 4.19%	8,520 $333,000
Q3 2022 Nov 14, 2022	BUY	$39.79 - $70.31 $104,607 - $184,844	2,629 Added 47.39%	8,177 $209,000
Q2 2022 Aug 15, 2022	BUY	$29.86 - $62.36 $21,588 - $45,086	723 Added 14.98%	5,548 $212,000
Q1 2022 May 16, 2022	SELL	$53.73 - $82.16 $17,999 - $27,523	-335 Reduced 6.49%	4,825 $276,000
Q4 2021 Feb 14, 2022	BUY	$68.02 - $99.06 $350,983 - $511,149	5,160 New	5,160 $411,000
Q3 2021 Nov 12, 2021	SELL	$84.37 - $133.6 $206,959 - $327,720	-2,453 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$64.12 - $128.71 $157,286 - $315,725	2,453 New	2,453 $316,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

Stay updated on Vident Investment Advisory, LLC with notifications on news.